(VHT) Health Care Shares - Overview
ETF Category: Health | Exchange: NYSE (USA) | Market Cap: 16.561m USD | Total Return: 16.9% in 12m
Avg Turnover: 62.4M
Warnings
Extended 3d
Tailwinds
No distinct edge detected
The Vanguard Health Care Index Fund ETF (VHT) utilizes a full-replication indexing strategy to track the performance of the MSCI US Investable Market Health Care 25/50 Index. This fund provides broad exposure across the entire market capitalization spectrum, including large, mid, and small-cap U.S. equities within the healthcare sector as defined by the Global Industry Classification Standard (GICS).
The healthcare sector typically encompasses diverse sub-industries such as pharmaceuticals, biotechnology, medical device manufacturing, and healthcare providers. Companies in this space often operate under high regulatory oversight and rely heavily on research and development (R&D) to maintain competitive advantages through patent protection and clinical innovation.
As a non-diversified fund, VHT may concentrate its assets in a smaller number of issuers compared to broader market indices, potentially increasing sensitivity to developments within specific healthcare segments. Investors should evaluate the underlying holdings on ValueRay to better understand the specific risk profile of this ETF. The fund has been active since 2004 and manages a large-cap portfolio focused on long-term capital appreciation within the domestic medical economy.
- Medicare drug price negotiations impact pharmaceutical and biotech margins
- GLP-1 weight loss drug demand drives pharmaceutical sector revenue growth
- Aging US demographics increase long-term demand for healthcare services
- Federal Reserve interest rate policy shifts impact biotech capital allocation
As of June 08, 2026, the stock is trading at USD 284.13 with a total of 405,956 shares traded.
Over the past week, the price has changed by +1.62%,
over one month by +4.81%,
over three months by -0.05% and
over the past year by +16.91%.
Health Care Shares has no consensus analysts rating.